20 articles
12-month trial examined whether oral MK-677 could restore youthful growth hormone levels and improve body composition in healthy seniors.
Pfizer's 24-month study of oral growth hormone secretagogue CP-424,391 in 396 at-risk elderly adults was terminated early.
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
A Phase IIa trial explores whether the HIF-PHI drug daprodustat can safely replace EPO injections in hemodialysis patients with anemia.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
Novel KH-1 supplement containing spermidine and probiotics tested for autophagy stimulation and glucose control in 42 prediabetic participants.
A completed trial investigates whether replenishing glutathione precursors can reverse metabolic dysfunction in elderly adults.
Small trial tests hormone-based therapy to combat age-related muscle and bone loss in vulnerable adults.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
A French trial investigated whether circulating immune cell profiles, specifically CD226 expression, could predict who responds to Atezolizumab/Bevacizumab in advanced HCC.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
A completed trial compares two endometrial prep strategies for IVF patients with moderate-to-severe intrauterine adhesions, a notoriously difficult fertility challenge.
A 12-week trial tested whether a bioactive hydrolysate could reduce gut discomfort, inflammation, and blood sugar issues in healthy elderly participants.
Phase 3 trial of IBI306, a PCSK9 inhibitor, tests LDL-C reduction in Chinese adults with high cardiovascular risk on statin therapy.
A completed RCT tests whether adding collagen peptides to standard calcium and vitamin D supplementation improves bone density and remodeling markers in women with osteopenia.
Austrian researchers tested whether donepezil could increase growth hormone levels and improve age-related body composition changes in elderly adults.
A first-in-human Phase 1 trial evaluates PF-07257876, a dual-checkpoint bispecific antibody targeting both CD47 and PD-L1, in hard-to-treat cancers.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
